1 :T1-2N ; 5. , ; ; 12. , ; 14., ; 15. , ; 16. , ; 17., ; 18.
|
|
|
- Scarlett Martin
- 7 years ago
- Views:
Transcription
1 The Journal of Evidence-Based Medicine Apr. 202 Vol.2 No.2 : ( [ ] [ ] R734.2 [ ] A [ ] ( The Consensus of Small Cell Lung Cancer Management / / WU Yi-long LIAO Mei-lin 2 ZHOU Qing-hua 3 CHENG Ying 4 WANG Chang-li 5 WANG Lü-hua 6 LU Shun 2 FU Xiao-long 7 ZHOU Cai-cun 8 HUANG Cheng 9 Tony SK Mok 0 LUO Dong-lan YANG Xue-ning WANG Jie CHEN Haiquan 7 LU You 2 WANG Jun 3 MA Sheng-lin 4 XU Lin 5 MAO Wei-min 6 FENG Ji-feng 5 SONG Qi-bin 7 WU Gang 8 ZHU Guang-ying WANG Zhen Key words: small cell lung cancer evidence-based medicine consensus First-author s address: Guangdong General Hospital Guangdong Academy of Medical Sciences Guangdong Lung Cancer Institute Guangzhou China 20 : A : ( Meta RCT B : ( Meta RCT 2A : 2B : 3 : :T-2N :2B (China society of clinical oncologycsco (small cell lung cancersclc + + [-2]
![2 [ ] A [ ] 67-544(20202-0065-05 The Consensus of Small Cell Lung Cancer Management / / WU Yi-long LIAO Mei-lin 2 ZHOU Qing-hua 3 CHENG Ying 4 WANG Chang-li 5 WANG Lü-hua 6 LU Shun 2 FU Xiao-long 7](/docs-images/48/23926844/images/page_1.jpg "ZHOU Cai-cun 8 HUANG Cheng 9 Tony SK Mok 0 LUO Dong-lan YANG Xue-ning WANG Jie CHEN Haiquan 7 LU You 2 WANG Jun 3 MA Sheng-lin 4 XU Lin 5 MAO Wei-min 6 FENG Ji-feng 5 SONG Qi-bin 7 WU Gang 8 ZHU")
2 : N Lally Oncologist N : 5 ~ % ~40% 5 :2A 0%~3% [3] 200 Yu N0 N N2 (surveillance epidemiology and end results evaluationseer 998- SEER N [4] N (5.8% 5 (P=0.0 [5] N 50.3% 636 (40.8% % [4] (P=0.79 Schreiber [5] SEER Schreiber [5] N0 N 4 79 (localizedt-t2nx-n0 (National Comprehensive Cancer Network NCCN (regionalt3-t4nx-n0 863 N N0 [9] 5 :N (P<0.00N N N (P<0.00N2 2 9 (P< : 5 [6-7 ] :B Auperin 999 New England Journal of Medicine Meta 2009 (Union for Internationale Cancer Control UICC 987 (International Association for the Study of Lung Cancer IASLC 6% [8] TNM ( % 0.73 ~0.9P = T-T2N0-N % 20.7% + 54%( % N2 0.38~0.57P<0.00 2B Gy
![79 Schreiber [5] SEER Schreiber [5] 988-2002 N0 N 4 79 (localizedt-t2nx-n0 (National Comprehensive Cancer Network NCCN (regionalt3-t4nx-n0 863 N N0 [9] 5 :N0 5 40 (P<0.00N N N2 4 29 (P<0.](/docs-images/48/23926844/images/page_2.jpg "00N2 2 9 (P<0.")
3 [0] 5 : + Meert [] Meta :B Slotman [2 ] 2007 New England (EP Journal of Medicine 286 4~6 5~ %~40% 70%~85% 73% ( 8~3 2 5% [8] % 0.6~0.44P< Noda New England Journal 4.6%. 67 of Medicine + (IP 40.4% EP IP 3.3% 27.% ( 2.8 EP 9.4 (P= % 0.52~0.68P= %5.2% [9] 20 Gy / 5 IP EP [20-2] (IC (EC IC EC 8.5 (IC7. (EC 34% 24% (.495%.06 ~.87P = 25 Gy 20 Gy 0.02 [22] Jiang [23] 4 Meta Auperin NCCN ( % 0.66~0.99 P= : >65 PS>2 6 : :2B :B % 38.6% 7%~3% [3] 4 8 [24] [4-5] %~40% [6] 3 [7] 0%
![52~0.68P=0.003 0.0022 9.5%5.2% [9] 20 Gy / 5 IP EP [20-2] (IC (EC IC EC 8.5 (IC7. (EC 34% 24% (.495%.06 ~.87P = 25 Gy 20 Gy 0.](/docs-images/48/23926844/images/page_3.jpg "02 [22] Jiang [23] 4 Meta Auperin NCCN ( 0.8 95% 0.66~0.99 P=0.044 4 : >65 PS>2 6 : :2B :B 200 207 6.4% 38.")
4 [25] T-2N0-M0 N2-3M0 Mb( + +PCI N2+ + CR PR+PCI Mb RR+PCI : : : : [] [2] [3] [4] [5] [6] [7] [8] [ ] Fox W Scadding JG. Medical research council comparative trial [EB / OL]. http: / / / professionals / physician_gls / f_ of surgery and radiotherapy for primary treatment of small-celled or oat-celled carcinoma of bronchus[j]. Lancet 9732(7820: [0] guidelines.asp. AupérinA Arriagada R Pignon JP et al. Prophylacticcranial Irradiation for patients with small-cell lung cancer in Lad T Piantadosi S Thomas Pet al. A prospective randomized completeremission[j]. N Engl J Med 99934(7: trial to determine the benefit of surgical resection of residual [] Meert A-P Paesmans M Berghmans T et al. Prophylactic disease following response of small cell lung cancer to cranial irradiation in small cell lung cancer: A systematic review combination chemotherapy [J]. Chest (6 Suppl: of the literature with meta-analysis[j]. BMC Cancer 200:5. 320S-323S. [2] Slotman B Faivre-Finn C Kramer G et al. Prophylactic Lally BE Urbanic JJ Blackstock AW et al. Small cell lung cranial irradiation in extensive small-cell lung cancer[j]. N Engl cancer: Have we made any progress over the last 25 years? J Med (7: [J]. Oncologist 20072(9: [3] Giuliani M Sun A Bezjak A et al. Utilization of prophylactic Yu JB Decker RH Detterbeck FC et al. Surveillance cranial irradiation in patients with limited stage small cell lung Epidemiology and End Results evaluation of the role of surgery for stagesmall cell lung cancer [J]. J Thorac Oncol 2005 (2: [4] carcinoma[j]. Cancer 2006(24: Sun A Bae K Gore EM et al. Phase trial of prophylactic cranial irradiation compared with observation inpatients with Schreiber D Rineer J Weedon J et al. Survival outcomes with locally advanced non-small-cell lung cancer: Neurocognitive the use of surgery in limited-stage small cell lung cancer [J]. Cancer 2006(5: andquality-of-life analysis [J]. J Clin Oncol 2029(3: [5] Le Péchoux C Laplanche A Faivre-Finn C et al. Clinical [J] (6: neurological outcome and quality of life among patients with. limited small-cell cancer treated with two different doses of [J] (6: Shepherd FA Crowley J Van Houtte P et al. The International Association for the Study of Lung Cancer lung cancer staging project: Proposals regarding the clinical staging of small cell lung cancer in the forthcoming (seventh edition of the tumor node metastasis classification for lung cancer [J]. J Thorac Oncol 20072(2: [9] NCCN Guidelines: Small cell lung cancer. Version prophylactic cranial irradiation in the intergroup phase trial (PCI99-0 EORTC RTOG 022 and IFCT 99-0[J]. Ann Oncol 2022(5: [6] Wolfson AH Bae K Komaki R et al. Primary analysis of phase randomized trial Radiation Therapy Oncology Group (RTOG 022: Impact of different total doses and schedules of prophylactic cranialirradiation on chronic neurotoxicity and
5 . 69 quality of life for patients with limited-disease small-cell lung small-cell lung cancer: Clinical and pharmacogenomic results cancer[j]. Int J Radiat Oncol Biol Phys 208(: from SWOG S024[J]. J Clin Oncol (5: [7] Slotman BJ Mauer ME Bottomley A et al. Prophylactic [22] Hermes A Bergman B Bremnes R et al. Irinotecan plus cranial irradiation in extensive disease small-cell lung cancer: Carboplatin versus oral Etoposide plus Carboplatin in extensive short-term health-related quality of life and patient reported small-cell lung cancer: A randomized phase trial [J]. J Clin symptoms: Results of aninternational phase randomized Oncol (26: controlled trial by the EORTC RadiationOncology and Lung [23] Jiang J Liang X Zhou X et al. A meta-analysis of randomized Cancer Groups[J]. J Clin Oncol (: controlled trials comparing Irinotecan / Platinum with Etoposide / [8] van Meerbeeck JP Fennell DA De Ruysscher DKM. Small-cell Platinum in patients with previously untreated extensive-stage lung cancer[j]. Lancet 20378(9804: small cell lung cancer [J]. J Thorac Oncol 2005 (6:867- [9] Noda K Nishiwaki Y Kawahara M et al. Irinotecan plus 873. Cisplatin compared with Etoposide plus Cisplatin for extensive [24] Jotte R Von Pawel J Spigel DR et al. Randomized phase small-cell lung cancer[j]. N Engl J Med (2:85-9. trial of Amrubicin versus Topotecan (Topo as second-line [20] Hanna N Bunn PA Langer C et al. Randomized phase treatment for small cell lung cancer (SCLC[J]. J Clin Oncol trial comparing Irinotecan / Cisplatin with Etoposide / Cisplatin in 2029 (suppl:abstr patients with previously untreated extensive-stage disease small- [25] Kim YH Mishima M. Second-line chemotherapy for small-cell cell lung cancer[j]. J Clin Oncol (3: lung cancer (SCLC[J]. Cancer Treat Rev 2037(2:43- [2] Lara PN Natale R Crowley J et al. Phase trial of Irinotecan / Cisplatin compared with Etoposide / Cisplatin in extensive-stage 50. [ ] !!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!!! 202 ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( 307 ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( ( (
Pulmonary function. Is patient potentially operable? Yes. tests 3. Yes. Pulmonary function. tests 3, if clinically indicated. Yes
INITIAL EVALUATION Pathology consistent with small cell lung cancer History and physical Chest X-ray Laboratory studies to include: hematological and full chemistry panels CT chest and upper abdomen Pet
SMALL CELL LUNG CANCER
Protocol for Planning and Treatment The process to be followed in the management of: SMALL CELL LUNG CANCER Patient information given at each stage following agreed information pathway 1. DIAGNOSIS New
Treatment of Small Cell Lung Cancer
Chapter 5 Treatment of Small Cell Lung Cancer Ariel Lopez-Chavez MD, MS Introduction There are two main types of lung cancer, non-small cell lung cancer and small cell lung cancer. 1 It is important that
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology. Endorsement of the American College of Chest Physicians (ACCP) Guideline
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline Table of Contents Data Supplement 1: Summary of included
4.8 Lung cancer. 4.8.5 In the UK, three fractionation regimens are most commonly used:
4.8 Lung cancer 4.8.1 In 2005, both NICE (National Institute for Health and Clinical Excellence) and SIGN (Scottish Intercollegiate Guidelines Network) published guidelines on the management of lung cancer.
LUNG CANCER INTRODUCTION
LUNG CANCER INTRODUCTION Lung cancer remains the leading cause of cancer death in the UK. Approximately 50% of those diagnosed present with stage IV disease. Significant advances in the management of lung
Small Cell Lung Cancer
Small Cell Lung Cancer Lung Practice Guideline Dr. Brian Dingle MSc, MD, FRCPC Approval Date: April 2007 Revised: November 2008 This guideline is a statement of consensus of the Thoracic Disease Site Team
Lung cancer is the number one cancer cause of mortality
ORIGINAL ARTICLE Prognostic Factors for Survival in Extensive Stage Small Cell Lung Cancer (ED-SCLC) The Importance of Smoking History, Socioeconomic and Marital Statuses, and Sai-Hong Ignatius Ou, MD,
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline
Treatment of Small Cell Lung Cancer: American Society of Clinical Oncology Endorsement of the American College of Chest Physicians (ACCP) Guideline An ASCO Endorsement of Treatment of Small Cell Lung Cancer:
Small Cell Lung Cancer
Small Cell Lung Cancer Types of Lung Cancer Non-small cell carcinoma (NSCC) (87%) Adenocarcinoma (38%) Squamous cell (20%) Large cell (5%) Small cell carcinoma (13%) Small cell lung cancer is virtually
Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy on limited small cell lung cancer
[Chinese Journal of Cancer 27:10, 353-357; October 2008]; 2008 Sun Yat-Sen University Cancer Center Clinical Research Paper Efficacy of chemotherapy combined hyperfractionated accelerated radiotherapy
NCCN Non-Small Cell Lung Cancer V.1.2011 Update Meeting 07/09/10
Guideline Page and Request NSCL-3 Stage IA, margins positive delete the recommendation for chemoradiation. Stage IB, IIA, margins positive delete the recommendation for chemoradiation + Stage IIA, Stage
clinical practice guidelines
clinical practice guidelines Annals of Oncology 21 (Supplement 5): v120 v125, 2010 doi:10.1093/annonc/mdq172 Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
Update on Small Cell Lung Cancer
Welcome to Master Class for Oncologists Session 3: 2:45 PM - 3:30 PM Washington, DC March 28, 2009 Small Cell Lung Cancer: Best Practices & Recent Advances Speaker: Bruce E. Johnson, MD Professor of Medicine,
Management of stage III A-B of NSCLC. Hamed ALHusaini Medical Oncologist
Management of stage III A-B of NSCLC Hamed ALHusaini Medical Oncologist Global incidence, CA cancer J Clin 2011;61:69-90 Stage III NSCLC Includes heterogeneous group of patients with differences in the
Survival analysis of 220 patients with completely resected stage II non small cell lung cancer
窑 Original Article 窑 Chinese Journal of Cancer Survival analysis of 22 patients with completely resected stage II non small cell lung cancer Yun Dai,2,3, Xiao Dong Su,2,3, Hao Long,2,3, Peng Lin,2,3, Jian
American College of Radiology ACR Appropriateness Criteria RADIATION THERAPY FOR SMALL-CELL LUNG CANCER
Date of origin: 2012 American College of Radiology ACR Appropriateness Criteria RADIATION THERAPY FOR SMALL-CELL LUNG CANCER Expert Panel on Radiation Oncology Lung: Feng-Ming (Spring) Kong, MD, PhD, MPH
Moving towards novel treatments in mesothelioma. Paul Baas, The Netherlands Cancer Institute Rolf Stahel, University Clinic Zurich
Moving towards novel treatments in mesothelioma Paul Baas, The Netherlands Cancer Institute Rolf Stahel, University Clinic Zurich Malignant pleural mesothelioma (MPM) has proven to be quite resistant to
Cesare Gridelli 1, Francesca Casaluce 2, Assunta Sgambato 2, Fabio Monaco 3, Cesare Guida 4
Editorial Treatment of limited-stage small cell lung cancer in the elderly, chemotherapy vs. sequential chemoradiotherapy vs. concurrent chemoradiotherapy: that s the question Cesare Gridelli 1, Francesca
Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board
Management of Stage III, N2 NSCLC: A Virtual Thoracic Oncology Tumor Board Abstract Introduction Management of stage III non small-cell lung cancer (NSCLC) is complex and requires careful work-up, staging,
Radiation Therapy in the Treatment of
Lung Cancer Radiation Therapy in the Treatment of Lung Cancer JMAJ 46(12): 537 541, 2003 Kazushige HAYAKAWA Professor and Chairman, Department of Radiology, Kitasato University School of Medicine Abstract:
Is an evidence-based approach realistic in non-small cell lung cancer (NSCLC)?
Is an evidence-based approach realistic in non-small cell lung cancer (NSCLC)? Authors Key words P.A. Coucke, N. Barthelemy, L. Bosquee, J.P. van Meerbeeck NSCLC, sequential and concomitant chemo-radiotherapy,
Stage IIIB disease includes patients with T4 tumors,
Guidelines on Treatment of Stage IIIB Non-small Cell Lung Cancer* James R. Jett, MD, FCCP; Walter J. Scott, MD, FCCP; M. Patricia Rivera MD, FCCP; and William T. Sause, MD, FACR Stage IIIB includes patients
The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy
17 (Supplement 10): x108 x112, 2006 doi:10.1093/annonc/mdl247 The expanding role of systemic treatment in non-small cell lung cancer neo-adjuvant therapy E. Felip & E. Vilar Oncology Department, Vall d
Docteur Oswald VAN CUTSEM Pneumologue Chef de Service
Docteur Oswald VAN CUTSEM Pneumologue Chef de Service Contacts secrétariat planning : 081. 20 96 61 secrétariat consultations : 081. 20 94 61 Diplômes : Doctorat UCL 1983 Diplôme de spécialiste en pneumologie
2.2.5 Target Volumes in Small Cell Lung Cancer
Target Volumes in Small Cell Lung Cancer 111 2.2.5 Target Volumes in Small Cell Lung Cancer Yolanda I. Garces and James A. Bonner CONTENTS 2.2.5.1 Introduction 111 2.2.5.2 Tumor Volume Definitions 111
Clinical Commissioning Policy: Stereotactic Ablative Body Radiotherapy for Non- Small-Cell Lung Cancer (Adult) April 2013 Reference: NHSCB/B01/P/a
Clinical Commissioning Policy: Stereotactic Ablative Body Radiotherapy for Non- Small-Cell Lung Cancer (Adult) April 2013 Reference: NHS Commissioning Board Clinical Commissioning Policy: Stereotactic
Small-Cell Lung Cancer: Is There a Standard Therapy?
Small-Cell Lung Cancer: Is There a Standard Therapy? Review Article [1] January 02, 1998 By Pieter E. Postmus, MD, PhD [2] and Egbert F. Smit, MD [3] For more than 25 years, chemotherapy has been the cornerstone
Small Cell Lung Cancer* State-of-the-Art Therapy 1994
Small Cell Lung Cancer* State-of-the-Art Therapy 1994 Daniel C. Ihde, MD In the United States, small cell lung cancer (SCLC) accounts for about 20% of all cases of lung cancer. Without treatment, tumor
Who may benefit from prophylactic cranial irradiation amongst stage III non-small cell lung cancer patients?
JBUON 2013; 18(2): 453-458 ISSN: 1107-0625 www.jbuon.com E-mail: info@jbuon.com ORIGINAL ARTICLE Who may benefit from prophylactic cranial irradiation amongst stage III non-small cell lung cancer patients?
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof.
Corso Integrato di Clinica Medica ONCOLOGIA MEDICA AA 2010-2011 LUNG CANCER. VIII. THERAPY. V. SMALL CELL LUNG CANCER Prof. Alberto Riccardi SMALL CELL LUNG CARCINOMA Summary of treatment approach * limited
Management of Small Cell Lung Cancer
Evidence Report/Technology Assessment Number 143 Management of Small Cell Lung Cancer Prepared for: Agency for Healthcare Research and Quality U.S. Department of Health and Human Services 540 Gaither Road
Probe: Could you tell me about when?
PERIODIC ASSESSMENT OF TREATMENT AND VITAL/DISEASE STATUS Periodic Assessment of Cancer Treatment and Disease Status (To be administered to patient at 3 months and reviewed at 6, 9 and 12 months) Instructions:
Mesothelioma. Malignant Pleural Mesothelioma
Mesothelioma William G. Richards, PhD Brigham and Women s Hospital Malignant Pleural Mesothelioma 2,000-3,000 cases per year (USA) Increasing incidence Asbestos (50-80%, decreasing) 30-40 year latency
Small Cell Lung Cancer
NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ) Small Cell Lung Cancer Version 2.2014 NCCN.org Continue Version 2.2014 09/17/13 National Comprehensive Cancer Network, Inc. 2013, All rights
Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin
COMPENDIA TRANSPARENCY TRACKING FORM DRUG: Docetaxel INDICATION: Non-small cell lung cancer, advanced or metastatic, switch-therapy after gemcitabine/carboplatin COMPENDIA TRANSPARENCY REQUIREMENTS 1 Provide
New Approaches for Small-Cell Lung Cancer: Local Treatments
The current management of limited-disease small-cell lung cancer is reviewed, and strategies to improve local control are discussed. Gary Ernest Smith. Sorting Old Bales. Oil on canvas, 18 24. Courtesy
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART
Harmesh Naik, MD. Hope Cancer Clinic HOW DO I MANAGE STAGE 4 NSCLC IN 2012: STATE OF THE ART Goals Discuss treatment options for stage 4 lung cancer: New and old Discuss new developments in personalized
Underutilization of Radiotherapy for Lung Cancer in New South Wales, Australia
Underutilization of Radiotherapy for Lung Cancer in New South Wales, Australia Shalini K. Vinod, MBBS, MD, FRANZCR 1 ; Leonardo Simonella, BA, MPH 2 ; David Goldsbury, BSc, MPH 2 ; Geoff P. Delaney, MBBS,
Lung Cancer Treatment Guidelines
Updated June 2014 Derived and updated by consensus of members of the Providence Thoracic Oncology Program with the aid of evidence-based National Comprehensive Cancer Network (NCCN) national guidelines,
RadioTherapy Timing in Small Cell Lung Cancer
RadioTherapy Timing in Small Cell Lung Cancer A meta-analysis of randomised trials using individual patient data on the timing of chest radiotherapy in patients with limited stage small cell lung cancer
the standard of care 2009 5/1/2009 Mesothelioma: The standard of care take home messages PILC 2006 Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009
Mesothelioma: The standard of care Jan.vanmeerbeeck@ugent.be Brussels, March 7, 2009 take home messages PILC 2006 All patients should receive adequate palliation of dyspnea and pain before starting chemotherapy
Controversies in Management of. Inoperable NSCLC. Inoperable NSCLC. Introduction:
Inoperable NSCLC Controversies in Management of Inoperable NSCLC Introduction: It is difficult to overemphasize the magnitude of lung cancer as Public Health Problem in our society. - In US, Lung cancer
Out-Patient Chemotherapy for Lung Cancer
Lung Cancer Out-Patient Chemotherapy for Lung Cancer Principles and practice JMAJ 46(12): 542 546, 2003 Shuichi YONEDA Director, Department of Pulmonary Medicine, Saitama Cancer Center Abstract: Recent
The New International Staging System Lung Cancer
The New International Staging System Lung Cancer Valerie W. Rusch, MD Chief, Thoracic Surgery Memorial Sloan-Kettering Cancer Center Chair, Lung and Esophagus Task Force, American Joint Commission on Cancer
Epidemiology, Staging and Treatment of Lung Cancer. Mark A. Socinski, MD
Epidemiology, Staging and Treatment of Lung Cancer Mark A. Socinski, MD Associate Professor of Medicine Multidisciplinary Thoracic Oncology Program Lineberger Comprehensive Cancer Center University of
Small Cell Lung Cancer
78 NCCN Small Cell Lung Cancer Clinical Practice Guidelines in Oncology Gregory P. Kalemkerian, MD; Wallace Akerley, MD; Paul Bogner, MD; Hossein Borghaei, DO, MS; Laura QM Chow, MD; Robert J. Downey,
Table of Contents. Data Supplement 1: Summary of ASTRO Guideline Statements. Data Supplement 2: Definition of Terms
Definitive and Adjuvant Radiotherapy in Locally Advanced Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Endorsement of the American Society for Radiation
Results of Surgical Treatment for Small Cell Lung Cancers
NAOSITE: Nagasaki University's Ac Title Author(s) Results of Surgical Treatment for S Ayabe, Hiroyoshi; Nakamura, Akihiro Hara, Shinsuke; Tagawa, Yutaka; Kaw Citation Acta medica Nagasakiensia. 1994, 39
Lung Cancer - Combination Chemotherapy and the Risk of Failure
Evidence-based Series 7-13-1 Version 2 A Quality Initiative of the Program in Evidence-Based Care (PEBC), Cancer Care Ontario (CCO) The Role of Combination Chemotherapy in the Initial Management of Limited-Stage
Lung Cancer and Mesothelioma
Lung Cancer and Mesothelioma Robert Kratzke, M.D. John C. Skoglund Professor of Lung Cancer Research Section of Heme/Onc/Transplant Department of Medicine University of Minnesota Medical School Malignant
CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER
CHAPTER 6: TREATMENT FOR SMALL CELL LUNG CANCER INTRODUCTION This chapter provides an overview of treatment for small cell lung cancer (SCLC). Treatment options are presented based on the extent of disease.
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress
Non Small Cell Lung Cancer: Scientific Discoveries and the Pursuit of Progress Lung Cancer Accounts for 14% of All New Cancer Diagnoses in the United States 1 Lung cancer is the second most common malignancy
What is neuroendocrine cervical cancer?
Key Points: 1. Neuroendocrine cancer of the uterine cervix is a rare and aggressive disease. 2. Treatment for neuroendocrine cervical cancer is usually more intensive than that for most other types of
Adjuvant Therapy Non Small Cell Lung Cancer. Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015
Adjuvant Therapy Non Small Cell Lung Cancer Sunil Nagpal MD Director, Thoracic Oncology Jan 30, 2015 No Disclosures Number of studies Studies Per Month 12 10 8 6 4 2 0 1 2 3 4 5 6 7 8 9 10 11 12 1 2 3
London Cancer. Mesothelioma Lung Protocols
London Cancer Mesothelioma Lung Protocols Version 0.9 Contents 1. Staging... 3 2. Mesothelioma Summary of Chemotherapy Protocols... 4 3. Mesothelioma Chemotherapy Protocols... 7 3.1. Pemetrexed (Alimta
Current concepts in the management of small cell lung cancer
Review Article Indian J Med Res 137, June 2013, pp 1043-1051 Current concepts in the management of small cell lung cancer Apar Kishor Ganti 1,2, William W. West 3 & Weining Zhen 4, 1 Section of Hematology-Oncology,
Multidisciplinary Therapy of Stage IIIA Non Small-Cell Lung Cancer: Long-term Outcome of Chemoradiation With or Without Surgery
Special Report Multidisciplinary Therapy of Stage IIIA Non Small-Cell Lung Cancer: Long-term Outcome of Chemoradiation With or Without Surgery Charu Aggarwal, MD, Linna Li, MD, Hossein Borghaei, DO, Ranee
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer
Protein kinase C alpha expression and resistance to neo-adjuvant gemcitabine-containing chemotherapy in non-small cell lung cancer Dan Vogl Lay Abstract Early stage non-small cell lung cancer can be cured
Implementation Date: April 2015 Clinical Operations
National Imaging Associates, Inc. Clinical guideline PROSTATE CANCER Original Date: March 2011 Page 1 of 5 Radiation Oncology Last Review Date: March 2015 Guideline Number: NIA_CG_124 Last Revised Date:
CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015. 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV
CANCER PULMON: ESTADIOS INICIALES POSTMUNDIAL PULMON DENVER 2015 8-10-2015.Manuel Cobo Dols S. Oncología Médica HU Málaga Regional y VV Meta-analisis LACE: adyuvancia vs no adyuvancia Pignon JP, et al.
Emerging Drug List GEFITINIB
Generic (Trade Name): Manufacturer: Gefitinib (Iressa ) formerly referred to as ZD1839 AstraZeneca NO. 52 JANUARY 2004 Indication: Current Regulatory Status: Description: Current Treatment: Cost: Evidence:
Once vs. Twice Daily Thoracic Irradiation in Limited Stage Small Cell Lung Cancer
J. Korean Soc Ther Radiol Oncol : Vol. 16, No. 3, September, 1998 Once vs. Twice Daily Thoracic Irradiation in Limited Stage Small Cell Lung Cancer Jun Sang Kim, M.D.*, Jae Sung Kim, M.D.*, Ju Ock Kim,
How To Improve Lung Cancer Survival With Radiation Therapy
Clinical Controversies: Proton Therapy for Thoracic Tumors Dirk De Ruysscher, MD, PhD,* and Joe Y. Chang, MD, PhD Photon and proton therapy techniques have both improved dramatically over the past decade.
REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group
REPORT ASCO 1998 LOS ANGELES : LUNG CANCER Johan F. Vansteenkiste, MD, PhD, Univ. Hospital and Leuven Lung Cancer Group Educational session Treatment of stage III non-small cell lung cancer (NSCLC) in
Lung Cancer. Public Outcomes Report. Submitted by Omar A. Majid, MD
Public Outcomes Report Lung Cancer Submitted by Omar A. Majid, MD Lung cancer is the most common cancer-related cause of death among men and women. It has been estimated that there will be 226,1 new cases
NON-SMALL CELL LUNG CANCER STAGE III
NON-SMALL CELL LUNG CANCER STAGE III Effective Date: April, 2012 The recommendations contained in this guideline are a consensus of the Alberta Provincial Thoracic Tumour Team synthesis of currently accepted
Post-recurrence survival in completely resected stage I non-small cell lung cancer with local recurrence
Post- survival in completely resected stage I non-small cell lung cancer with local J-J Hung, 1,2,3 W-H Hsu, 3 C-C Hsieh, 3 B-S Huang, 3 M-H Huang, 3 J-S Liu, 2 Y-C Wu 3 See Editorial, p 185 c A supplementary
Treatment of Stage III Non-small Cell Lung Cancer
CHEST Supplement DIAGNOSIS AND MANAGEMENT OF LUNG CANCER, 3RD ED: ACCP GUIDELINES Treatment of Stage III Non-small Cell Lung Cancer Diagnosis and Management of Lung Cancer, 3rd ed: American College of
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA)
NEOPLASMS OF KIDNEY (RENAL CELL CARCINOMA) And RENAL PELVIS (TRANSITIONAL CELL CARCINOMA) Merat Esfahani, MD Medical Oncologist, Hematologist Cancer Liaison Physician SwedishAmerican Regional Cancer Center
Lung Cancer: More than meets the eye
Lung Cancer Education Program November 23, 2013 Lung Cancer: More than meets the eye Shantanu Banerji MD, FRCPC Presenter Disclosure Faculty: Shantanu Banerji Relationships with commercial interests: Grants/Research
Stomach (Gastric) Cancer. Prof. M K Mahajan ACDT & RC Bathinda
Stomach (Gastric) Cancer Prof. M K Mahajan ACDT & RC Bathinda Gastric Cancer Role of Radiation Layers of the Stomach Mucosa Submucosa Muscularis Serosa Stomach and Regional Lymph Nodes Stomach and Regional
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines
Non-Small Cell Lung Cancer Treatment Comparison to NCCN Guidelines April 2008 (presented at 6/12/08 cancer committee meeting) By Shelly Smits, RHIT, CCS, CTR Conclusions by Dr. Ian Thompson, MD Dr. James
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER
GUIDELINES FOR THE MANAGEMENT OF LUNG CANCER BY Ali Shamseddine, MD (Coordinator); as04@aub.edu.lb Fady Geara, MD Bassem Shabb, MD Ghassan Jamaleddine, MD CLINICAL PRACTICE GUIDELINES FOR THE TREATMENT
Radiotherapy in locally advanced & metastatic NSC lung cancer
Radiotherapy in locally advanced & metastatic NSC lung cancer Dr Raj Hegde. MD. FRANZCR Consultant Radiation Oncologist. William Buckland Radiotherapy Centre. Latrobe Regional Hospital. Locally advanced
SMALL. 1-800-298-2436 LungCancerAlliance.org
Understanding series SMALL CELL LUNG CANCER 1-800-298-2436 LungCancerAlliance.org A guide for the patient I TABLE OF CONTENTS ANATOMY OF THE LUNGS The following image shows different parts that make up
Cetuximab (Erbitux) MM.04.005 05/10/2005. HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s) of Service: Office: Outpatient
Cetuximab (Erbitux) Policy Number: Original Effective Date: MM.04.005 05/10/2005 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 01/01/2015 Section: Prescription Drugs Place(s)
Screening, early referral and treatment for asbestos related cancer
Screening, early referral and treatment for asbestos related cancer Marc de Perrot, MD, MSc, FRCSC Toronto Mesothelioma Research Program University of Toronto Asbestos related diseases Mesothelioma Lung
Small Cell Lung Cancer: An Update on Therapeutic Aspects
Review Article Small Cell Lung Cancer: An Update on Therapeutic Aspects Manisha Bhutani, Ashutosh Kumar Pathak, Anant Mohan 1, Randeep Guleria 1 and Vinod Kochupillai Department of Medical Oncology, Institute
Randomized trial on chest irradiation in extensive disease small cell lung cancer
Chest Radiotherapy Extensive stage Small cell lung cancer Trial Randomized trial on chest irradiation in extensive disease small cell lung cancer Study coordinator: Prof.dr. B.J. Slotman Dept. of Radiation
Carcinoma of the Cervix. Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology
Carcinoma of the Cervix Kathleen M. Schmeler, MD Associate Professor Department of Gynecologic Oncology Cervical Cancer Treatment Treatment Microinvasive (Stage IA1): Simple (extrafascial) hysterectomy/cone
ORIGINAL ARTICLE THORACIC ONCOLOGY
Ann Surg Oncol (2013) 20:1934 1940 DOI 10.1245/s10434-012-2800-x ORIGINAL ARTICLE THORACIC ONCOLOGY Predictors for Locoregional Recurrence for Clinical Stage III-N2 Non-small Cell Lung Cancer with Nodal
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM
REPORT PERSPECTIVES IN LUNG CANCER 2010 AMSTERDAM Valerie Van Damme, Isabelle Wauters, Johan Vansteenkiste Univ. Hospital Leuven and Leuven Lung Cancer Group Introduction Perspectives in Lung Cancer (PILC)
U.S. Food and Drug Administration
U.S. Food and Drug Administration Notice: Archived Document The content in this document is provided on the FDA s website for reference purposes only. It was current when produced, but is no longer maintained
LUNG CANCER TREATMENT REGIMENS (Part 1 of 7)
LUNG CANCER TREATMENT S (Part 1 of 7) Clinical Trials: The NCCN recommends cancer patient participation in clinical trials as the gold standard for treatment. Cancer therapy selection, dosing, administration,
Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians
Treatment Algorithms for the Management of Lung Cancer in NSW Guide for Clinicians Background The Cancer Institute New South Wales Oncology Group Lung (NSWOG Lung) identified the need for the development
Radiotherapy in Lung
Radiotherapy in Lung CancerAnatomy Oblique fissure in both lungs. Horizontal fissure in Right lung. Trachea bifurcates at the level of T5. Lymph nodes are divided into stations. Intrapulmonary, bronchopulmonary
Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008
Special Report Temporal Trends in Demographics and Overall Survival of Non Small-Cell Lung Cancer Patients at Moffitt Cancer Center From 1986 to 2008 Matthew B. Schabath, PhD, Zachary J. Thompson, PhD,
Activity of pemetrexed in thoracic malignancies
Activity of pemetrexed in thoracic malignancies Results of phase III clinical studies of pemetrexed in malignant pleural mesothelioma and non-small cell lung cancer show benefit P emetrexed (Alimta) is
Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent. Disclosure
Re irradiation Using HDR Interstitial Brachytherapy for Locally Recurrent Cervical lcancer Yasuo Yoshioka, MD Department of Radiation Oncology Osaka University Graduate School of Medicine Osaka, Japan
TRATTAMENTO COMBINATO RADIO- CHEMIOTERAPICO NEL III STADIO NSCLC
TRATTAMENTO COMBINATO RADIO- CHEMIOTERAPICO NEL III STADIO NSCLC Dr.ssa Sara Ramella Radioterapia Oncologica Campus Bio-Medico Trimodality therapy offers a promising chance of long-term survival Evidenze
What is the reference cytotoxic regimen in advanced gastric cancer?
What is the reference cytotoxic regimen in advanced gastric cancer? Florian Lordick Professor of Oncology Director of the University Cancer Center Leipzig (UCCL) Germany What we know from clinical research.
Radiotherapy in Lung Cancer. Dr. Vassilis Kouloulias. Radiotherapy in lung cancer. Dr. V. Kouloulias
Radiotherapy in Lung Cancer Dr. Vassilis Kouloulias Assistant Professor of Radiation Oncologist, 2 nd Dpt. Radiology, University of Athens, Greece. Key Words Small cell lung cancer (SCLC), Non-small cell
Small cell Lung cancer New Chemotherapy options. Nicolas Mach, MD,PD
Small cell Lung cancer New Chemotherapy options Nicolas Mach, MD,PD > 40 negative Phase III trials List of unsucessful drugs Pemetrexed, imatinib, bevacizumab, bcl-2 antagonist, ASCT, CASE PRESENTATION
Report on New Patented Drugs - Alimta
Report on New Patented Drugs - Alimta Under its transparency initiative, the PMPRB publishes the results of the reviews of new patented drugs by Board Staff, for purposes of applying the PMPRB s Excessive
Adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer: new insights into
Annals of Oncology Advance Access published September 5, 2014 1 Adjuvant cisplatin-based chemotherapy in non-small-cell lung cancer: new insights into the effect on failure type via a multistate approach
Squamous Cell Carcinoma of Anal Canal Treatment Guidelines
May 2009 Squamous Cell Carcinoma of Anal Canal Treatment Guidelines Presented at Cancer Committee: August 6, 2009 By Shelly Smits, RHIT, CCS, CTR Conclusions by Ian Thompson, MD Data Source: Cancer registry
Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer
CLINICAL STUDY Effects of Chemotherapy on Quality of Life for Patients with Lung Cancer Ahmet Bircan, MD 1 ; M. Bahad r Berktafl, MD 1 ; Hülya Bay z, MD 1 ; Nihal Baflay, MD 1 ; Sema Bircan, MD 2 ; Mine
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS
MOH Policy for dispensing NEOPLASTIC DISEASES DRUGS All prescriptions for antineoplastic drugs must be accompanied by the MOH special form. All the attachments mentioned on this form shall be submitted
Recent Trends in Management of Unresectable Non-Small Cell Lung Cancer (NSCLC)
Bahrain Medical Bulletin, Vol.23, No.4, December 2001 Recent Trends in Management of Unresectable Non-Small Cell Lung Cancer (NSCLC) Jalal Al-Maskati, MBChB, ABIM * Lung cancer is a major health problem